Kodiak Sciences (NASDAQ:KOD - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Kodiak Sciences to post earnings of ($0.89) per share for the quarter.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.20). On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Kodiak Sciences Price Performance
KOD traded up $0.21 on Monday, reaching $3.71. 310,851 shares of the company's stock were exchanged, compared to its average volume of 350,092. The stock has a market cap of $195.75 million, a PE ratio of -1.02 and a beta of 2.42. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $11.60. The stock's fifty day moving average price is $3.28 and its 200-day moving average price is $5.50.
Analyst Ratings Changes
Separately, HC Wainwright restated a "neutral" rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.
Check Out Our Latest Report on Kodiak Sciences
Hedge Funds Weigh In On Kodiak Sciences
Several institutional investors and hedge funds have recently bought and sold shares of KOD. Dynamic Technology Lab Private Ltd acquired a new position in Kodiak Sciences in the 1st quarter valued at about $94,000. Jane Street Group LLC boosted its holdings in Kodiak Sciences by 441.3% in the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock valued at $181,000 after purchasing an additional 52,705 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in Kodiak Sciences in the 1st quarter valued at about $188,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Stories
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
